Major Events - China Railway announced an investigation into the construction accident at the Qianzhai Yellow River Bridge, which resulted in 12 fatalities and 4 missing persons. The bridge is 1596.2 meters long with a contract value of approximately 436 million yuan. The company stated that this incident will not have a significant impact on its operations and performance [4] - Greenme announced plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [5] - Jingwang Electronics plans to invest 5 billion yuan in the Zhuhai Jinwan base expansion project, focusing on high-growth areas such as AI computing power and automotive intelligence [6][7] - Mingtai Aluminum intends to sell a 2.5% stake in Sanmenxia Aluminum to Jiaozuo Wanfang, with the share price set at 5.39 yuan per share, expecting to receive 149 million shares [8] - Dingsheng New Materials also plans to sell a 0.57% stake in Sanmenxia Aluminum under similar terms [9] Performance Overview - Xiyu Co. reported a net profit of 1.062 billion yuan for the first half of 2025, a year-on-year increase of 32.76%, with total revenue of 21.093 billion yuan, up 12.35% [10] - Jintailang reported a net profit of 358 million yuan, a 3.95% increase, with revenue of 9.528 billion yuan, up 2.49% [11] - Huaxia Eye Hospital achieved a net profit of 282 million yuan, a 6.2% increase, with revenue of 2.139 billion yuan, up 4.31% [12] - Juxin Technology reported a net profit growth of 123.19%, reaching 91.375 million yuan, with revenue of 449 million yuan, up 60.12% [13][14] - Zhendong Pharmaceutical reported a net profit of 7.9313 million yuan, a decline of 74.13%, with revenue of 1.457 billion yuan, down 3.3% [15] - China Merchants South Oil reported a net profit decline of 53.28%, totaling 570 million yuan, with revenue of 2.772 billion yuan, down 21.43% [16] - Chongqing Construction reported a net loss of 249 million yuan, with revenue of 14.359 billion yuan, down 7.97% [17] - Huacan Optoelectronics reported a net loss of 115 million yuan, with revenue of 2.532 billion yuan, up 33.93% [18] - Digital Government reported a net loss of 18.6927 million yuan, with revenue of 321 million yuan, down 40.34% [19] Major Contracts - Zhonggong International signed a contract for an overseas road engineering project in Nicaragua, valued at approximately 513 million yuan, which represents 4.2% of the company's total revenue for 2024 [20] Shareholding Changes - Tiancheng Technology announced that shareholder Qingxun Electronics plans to reduce its stake by up to 119,000 shares, representing no more than 0.1% of the total share capital [22] - Ailong Technology's controlling shareholder plans to reduce its stake by up to 1.69% through various trading methods [23]

Group 1 - The core viewpoint of the article is that Huaxia Eye Hospital (301267) reported its semi-annual financial results, showing growth in both revenue and net profit [1] - The company achieved a revenue of 2.139 billion yuan in the first half of the year, representing a year-on-year increase of 4.31% [1] - The net profit attributable to shareholders was 282 million yuan, reflecting a year-on-year growth of 6.2% [1]

Group 1 - China Railway announced an investigation into the construction accident at the Qianzhai Yellow River Bridge, resulting in 12 fatalities and 4 missing persons. The bridge is 1596.2 meters long with a contract value of approximately 436 million yuan. The company stated that the accident will not have a significant impact on its operations and performance [3] - Greenme announced plans to issue H-shares and list on the main board of the Hong Kong Stock Exchange [4] - Jingwang Electronics plans to invest 5 billion yuan in the Zhuhai Jinwan base expansion project, focusing on high-growth areas such as AI computing power and autonomous driving from 2025 to 2027 [5] Group 2 - Xiyu Co. reported a net profit of 1.062 billion yuan for the first half of 2025, a year-on-year increase of 32.76%, with total revenue of 21.093 billion yuan [9] - Jintai Co. reported a net profit of 358 million yuan for the first half of 2025, a year-on-year increase of 3.95%, with total revenue of 9.528 billion yuan [10] - Huaxia Eye Hospital reported a net profit of 282 million yuan for the first half of 2025, a year-on-year increase of 6.2%, with total revenue of 2.139 billion yuan [11] - Juxin Technology reported a net profit of 91.375 million yuan for the first half of 2025, a year-on-year increase of 123.19%, with total revenue of 449 million yuan [13] - Zhendong Pharmaceutical reported a net profit of 7.9313 million yuan for the first half of 2025, a year-on-year decrease of 74.13%, with total revenue of 1.457 billion yuan [14] - China Merchants Nan Oil reported a net profit of 570 million yuan for the first half of 2025, a year-on-year decrease of 53.28%, with total revenue of 2.772 billion yuan [15] - Chongqing Construction reported a net loss of 249 million yuan for the first half of 2025, with total revenue of 14.359 billion yuan, a year-on-year decrease of 7.97% [16] - Huacan Optoelectronics reported a net loss of 115 million yuan for the first half of 2025, with total revenue of 2.532 billion yuan, a year-on-year increase of 33.93% [17] - Digital Government reported a net loss of 18.6927 million yuan for the first half of 2025, with total revenue of 321 million yuan, a year-on-year decrease of 40.34% [18] Group 3 - Zhonggong International signed a contract for an overseas road engineering project in Nicaragua worth approximately 513 million yuan, which accounts for 4.2% of the company's total revenue for 2024 [20]

Core Insights - Huaxia Eye Hospital (301267) reported its semi-annual results for 2025, showing a revenue of 2.139 billion yuan, representing a year-on-year growth of 4.31% [1] - The net profit attributable to shareholders reached 282 million yuan, with a year-on-year increase of 6.2% [1] - Basic earnings per share were reported at 0.34 yuan [1]

Company Overview - Huaxia Eye Hospital Group Co., Ltd. was established in 2004 and is located at 999 Wutong West Road, Huli District, Xiamen City [1] - The company specializes in providing various diagnostic and treatment services for eye diseases, as well as preventive interventions for vision issues [1] - The registered capital of the company is 840 million RMB, and the legal representative is Su Qingcan [1] Financial Performance - For the first half of 2025, the total operating revenue was 2.139 billion RMB, representing a year-on-year increase of 4.31% [1] - The net profit for the same period was 282 million RMB, showing a year-on-year growth of 6.20% [1] - Earnings per share were 0.34 RMB, with a return on equity of 4.8% [1] - The operating cash flow per share was 0.5046 RMB, and the gross profit margin was 45.20% [1] Investment and Intellectual Property - The company has made investments in 78 enterprises and participated in 15 bidding projects [1] - In terms of intellectual property, Huaxia Eye Hospital holds 66 trademark registrations and 38 patents [1] - The company also possesses 6 administrative licenses [1]

格隆汇8月24日丨华厦眼科(301267.SZ)公布2025年半年度报告，报告期实现营业收入21.39亿元，同比增 长4.31%；归属于上市公司股东的净利润2.82亿元，同比增长6.20%；归属于上市公司股东的扣除非经常 性损益的净利润2.78亿元，同比增长2.43%；基本每股收益0.34元。 ...

华厦眼科医院集团股份有限公司 证券代码：301267 证券简称： 华厦眼科 公告编号：2025-024 2025 年半年度报告披露的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特此公告。 华厦眼科医院集团股份有限公司董事会 2025 年 8 月 25 日 华厦眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 8 月 21 日 召开了第三届董事会第十次会议和第三届监事会第十次会议，审议通过了《2025 年半年度报告》及《2025 年半年度报告摘要》。 为使投资者全面了解公司的经营成果和财务状况，公司《2025 年半年度报 告》及《2025 年半年度报告摘要》已于 2025 年 8 月 25 日在中国证监会指定创 业板信息披露网站巨潮资讯网（http://www.cninfo.com.cn）上披露，敬请广大投 资者注意查阅。 ...

中国国际金融股份有限公司 关于华厦眼科医院集团股份有限公司 一、募集资金投资项目的基本情况 经中国证券监督管理委员会《关于同意华厦眼科医院集团股份有限公司首次公开发 行股票注册的批复》（证监许可〔2022〕2085 号）同意，公司首次公开发行人民币普通 股（A 股）6,000.00 万股，每股发行价为人民币 50.88 元，募集资金总额为人民币 305,280.00 万元，扣除不含增值税的发行费用人民币 28,430.75 万元后，实际募集资金 净额为人民币 276,849.25 万元。上述募集资金已于 2022 年 10 月 28 日到账，容诚会计 师事务所（特殊普通合伙）对募集资金到位情况进行了审验，并出具了容诚验字 [2022]361Z0068 号《验资报告》。公司对募集资金采取了专户存储制度，上述募集资金 到账后，已存放于募集资金专户。 公司《首次公开发行股票并在创业板上市招股说明书》披露的首次公开发行股票募 集资金投资项目及募集资金使用计划如下： 序号 募集资金投资项目 总投资 募集资金承诺投资金额 1 天津华厦眼科医院项目 61,000,000.00 61,000,000.00 2 区域视光中心建 ...

华厦眼科医院集团股份有限公司 防范控股股东及关联方资金占用管理制度 第一章 总则 第一条 为了加强和规范华厦眼科医院集团股份有限公司（以下简称"公 司"）的资金管理，建立防止控股股东及其他关联方占用公司资金的长效机制， 杜绝控股股东及其他关联方资金占用行为的发生，保护公司、股东及其他利益相 关人的合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、中国证监会《上市公司监管指 引第 8 号——上市公司资金往来、对外担保的监管要求》、《深圳证券交易所创业 板股票上市规则》（以下简称"《上市规则》"）以及《华厦眼科医院集团股份有限 公司章程》（以下简称"《公司章程》"）的有关规定，结合公司实际，制定本制度。 第二条 公司控股股东、实际控制人及其他关联方应严格依法行使出资人 的权利，对公司和公司股东负有诚信义务，不得通过资金占用等方式损害公司利 益和股东的合法权益。 第三条 本制度所称资金占用包括但不限于：经营性资金占用和非经营性 资金占用。经营性资金占用是指公司控股股东、实际控制人及其他关联方通过采 购、销售等生产经营环节的关联交易产生的资金占用； ...

华厦眼科医院集团股份有限公司 对外投资管理制度 第一章 总则 第一条 为规范华厦眼科医院集团股份有限公司（以下简称"公司"）的 对外投资行为，提高投资效益，规避投资所带来的风险，有效、合理的使用资金， 使资金的时间价值最大化，依照《中华人民共和国公司法》（以下简称"《公司 法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第2号 ——创业板上市公司规范运作》等以及其他国家法律、法规的相关规定，结合《公 司章程》《股东会议事规则》《董事会议事规则》等公司制度，制定本制度。 第二条 本制度所称的对外投资是指公司为获取未来收益而将一定数量 的货币资金、股权，以及经评估后的实物或无形资产作价出资，对外进行各种形 式的投资活动。 第三条 按照投资期限的长短，公司对外投资分为短期投资和长期投资。 短期投资主要指公司购入的能随时变现且持有时间不超过一年（含一年）的投资， 包括各种股票、债券、基金、分红型保险等； 长期投资主要指投资期限超过一年，不能随时变现或不准备变现的各种投资， 包括债券投资、股权投资和其他投资等。包括但不限于下列类型： ...